Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858111 | 0.88 | ESR1 (0.47) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL4071348 | 0.86 | ESR1 (0.50) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL5418547 | 0.86 | ESR1 (0.50) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL12387505 | 0.83 | ESR1 (0.52) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL1366408 | 0.83 | ESR1 (0.52) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| Hydrochloric Acid SCHEMBL2315162 | 0.82 | ESR1 (0.51) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL1640514 | 0.82 | ESR1 (0.51) | ESR1ESR2HDAC6MCHR1CTNNB1 | |
| SCHEMBL7227822 | 0.81 | MCHR1 (0.55) | ESR1ESR2HDAC6MCHR1 | |
| SCHEMBL1367533 | 0.81 | ESR1 (0.64) | ESR1ESR2HDAC6MCHR1 | |
| SCHEMBL7423258 | 0.80 | ESR1 (0.57) | ESR1ESR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ESR1 850/4885ESR2 1305/4885HDAC6 3260/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ESR1 850/4885ESR2 1305/4885HDAC6 3260/4885 |
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | ESR1 103/4885ESR2 115/4885HDAC6 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.